NASDAQ:BRNS Barinthus Biotherapeutics Q2 2025 Earnings Results & Report $0.74 0.00 (0.00%) As of 10/9/2026 Barinthus Biotherapeutics missed analyst earnings expectations in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$0.52 versus the -$0.29 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 7, 2025TimeBefore Market OpensConference Call4:00 PM ET Barinthus Biotherapeutics EPS ResultsActual EPS-$0.52Consensus EPS -$0.29Beat/MissMissed by -$0.23One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersBarinthus Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBarinthus Biotherapeutics' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Barinthus Biotherapeutics Q2 2025 Earnings FAQ Did Barinthus Biotherapeutics beat earnings estimates for Q2 2025? Barinthus Biotherapeutics (NASDAQ:BRNS) reported earnings of -$0.52 per share for Q2 2025, missing the consensus estimate of -$0.29. The report was announced on Thursday, August 7, 2025. When is Barinthus Biotherapeutics' next earnings date? Barinthus Biotherapeutics' next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Barinthus Biotherapeutics on the company's earnings history page. Barinthus Biotherapeutics Earnings HeadlinesBarinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsAugust 24, 2026 | globenewswire.comBarinthus Biotherapeutics PLC ADR BRNSJuly 3, 2026 | morningstar.comMFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 10 at 1:00 AM | Weiss Ratings (Ad)Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNSMay 11, 2026 | businesswire.comBarinthus Biotherapeutics: Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApril 30, 2026 | finanznachrichten.deBarinthus in Green on Bringing Out Quarterly NumbersApril 30, 2026 | baystreet.caSee More Barinthus Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Barinthus Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Barinthus Biotherapeutics and other key companies, straight to your email. Email Address About Barinthus BiotherapeuticsBarinthus Biotherapeutics (NASDAQ:BRNS) plc (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing T-cell immunotherapies designed to treat autoimmune diseases. Its approach is intended to selectively modulate disease-causing immune responses while preserving broader immune-system function. The company’s pipeline includes VTP-1000, an investigational therapy being developed for celiac disease. Barinthus is also advancing additional preclinical and clinical programs that use its proprietary immune-modulation technologies to target other autoimmune conditions. The company’s development strategy focuses on antigen-specific tolerance, which aims to reduce harmful immune reactions against particular tissues or proteins. Barinthus Biotherapeutics was formerly known as Vaccitech plc and adopted its current name in 2024 as it sharpened its focus on autoimmune disease. The company is headquartered in the United Kingdom and operates as an international biotechnology business serving global healthcare and pharmaceutical markets. William Enright serves as chief executive officer.View Barinthus Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
